M agnetic resonance spectroscopy (MRS) is an imaging technique based on the detection of radiofrequency signals generated by spins of magnetic resonance active nuclei (such as 1 H, 31 P, 13 C, and 19 F) precessing in an external magnetic field (B 0 ). In clinical practice, MRS produces spectra from the patient with an anatomical/spatial reference. MRS is mainly based on 1 H, because hydrogen is one of the main elements in human body. In vivo MRS allows the analysis and quantification of metabolites present in a tissue in a noninvasive way (1) . MRS is based on the fact that protons in different molecules resonate at slightly different frequencies. This feature is secondary to the differences in the local electron cloud, which may shield the nucleus from the main magnetic field. Different metabolites containing the same nucleus exhibit characteristic chemical shifts in resonance frequency. In the oncologic field, abnormal metabolites may represent emerging tumor biomarkers. MRS allows the characterization of the metabolic changes associated with cancer (2) . Up to date, the main diagnostic value of 1 H-MRS in tumors has been the detection of elevated levels of choline-containing compounds or total choline at 3.2 ppm, which includes contributions from choline, phosphocholine, and glycerophosphocholine. The most consistent difference between the majority of normal tissues and tumors is usually found in choline levels. As a general rule, normal tissues display low choline levels, whereas tumors show high choline levels ( Fig. 1) , although several exceptions must be considered in clinical practice ( Fig. 2) (3) . Beside this, other metabolic pathways and their metabolites can be assessed using MRS; the significance/importance of a concrete metabolite is going to depend on different features such as the clinical scenario and the organ to be studied (Table 1) . Although 1 H-MRS has been fundamentally applied clinically to assist in diagnosing and monitoring brain, prostate, and breast cancer (4) , it has also been used to investigate other processes in the oncologic field, including other types of primary tumors and lymph node tumor involvement (2) (3) (4) (5) (6) . This article reviews the image acquisition and interpretation of 1 H-MRS for cancer evaluation, evaluates its strengths and limitations, and correlates metabolite peaks at 1 H-MRS with diagnostic and prognostic parameters of cancer in different anatomic areas.
Spectroscopic imaging: technical requisites
Technically, MRS acquisition is basically very similar to that of magnetic resonance imaging (MRI). However, an optimized preacquisition preparation, adequate spectral acquisition techniques, and advanced methods of analysis are needed for obtaining a clinically useful spectrum with an optimal signal-to-noise ratio (SNR) that allows the separation of the most significant metabolites. Different technical questions need to be considered for generating adequate MRS data.
Preacquisition preparation
MRS preparation demands that the magnetic field (B 0 ) is made as homogeneous as possible. This process is named shimming (7) (8) (9) (10) . Different circumstances, including motion artifacts and large air-tissue interfaces, lead to magnetic susceptibility artifacts. Therefore, thorax and abdomen are locations difficult to exam by MRS. Another important part of MRS exams is the suppression of water and fat signals. The water and fat signals are much stronger than the metabolite signals that we are interested in. This feature creates problems with the dynamic range of the magnetic resonance receiver systems, which distorts the baseline of the spectrum, making the other metabolite peaks invisible. Initially, saturation bands must be placed closely around the volume/organ of interest in order to suppress the strong water and fat signals from the surrounding tissue. Frequency selective radiofrequency pulses saturate the water signal (90º pulses or chemical shift selective-CHESS-pulses). On the other hand, lipid signal suppression can be obtained in several ways. Long echo time (TE) sequences attenuate lipid signals. In addition, regions that produce large lipid signals or have unacceptable field homogeneity can be presaturated. Finally, the use of lipid nulling sequences (such as short tau inversion recovery-STIR) can be considered. However, it must be also considered that frequency selective fat saturation pulses may interfere with the observation of metabolite peaks such as lactate or alanine.
Acquisition parameters
The most adequate MRS technique must be chosen depending on what metabolites and which organ are going to be studied.
MRS signal is inherently low and consequently imaging requires many averages and extremely limited field of view. SNR and chemical shift separation of metabolite peaks increase approximately linearly with the increase of the magnetic field. However, considering the relatively weak magnetic fields used in clinical practice, a limited chemical shift dispersion and J-coupling can cause spectral overlap and complicate the separation of metabolites (7) (8) (9) (10) . Two main sequences are used in clinical practice
Main points
• Magnetic resonance spectroscopy (MRS) allows the analysis and quantification of metabolites present in a tissue in a noninvasive way by locating their specific peaks.
• MRS allows the characterization of the metabolic changes associated with cancer, which are dependent on tumor type.
• MRS interpretation is mainly based on checking the elevation of certain characteristic metabolites or the absence or decrease of normal metabolites.
• MRS shows important limitations in the clinical field: it is technically complex, time-consuming, and requires complex data processing. MRS as a tumor biomarker. Although, as a general rule, tumors usually show high choline levels, low-grade malignant tumors may show a negative choline resonance peak at 3.22 ppm. Sagittal 3D contrast-enhanced fat-suppressed image of a 57-year-old woman with pure mucinous carcinoma at 2 minutes (left) shows an enhancing mass with irregular contour and kinetic curve type 3 (not shown). Single-voxel spectrum (right) shows no choline resonance peak in the mass.
for MRS acquisition: PRESS (point-resolved spectroscopy) and STEAM (stimulated echo acquisition mode). The PRESS sequence can be used in either single voxel spectroscopy (SVS) (where a single region is evaluated) or multi-voxel spectroscopy (MVS) (simultaneous spectrum acquisitions in multiple regions). PRESS sequence is most commonly used in clinical practice because it presents a better SNR and less sensitivity to motion. STEAM is used only in SVS, since it results in better water suppression and shorter TE than PRESS (10) . It must be considered that the observed metabolite peaks change depending on TE. Some metabolites like glutamine-glutamate (Glx), and myoinositol have a short relaxation time and as a result they are not visible on a long TE sequence. A short TE acquisition is considered when TE is <40 ms; while a long echo time is considered when TE is >135-288 ms. Some authors also consider including the description of intermediate TE for 135 ms. TE selection may be a key point when planning a spectroscopic exam.
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Preprocessing of MRS
Preprocessing of MRS signal and data evaluation are the final steps required for the clinical use of MRS. MRS data become useful in practice when a postprocessing protocol decodes these signals, which can be transformed in a list of spectral components from which metabolite relative concentrations can be determined (Fig. 3) . Therefore, acquired MRS signals require a preprocessing protocol for improving the quantitation of metabolites (10) . Preprocessing protocols can be divided into two main classes depending on whether it is performed in the time domain or in the frequency domain. The traditional way to determine the different resonances present in this complex signal (free induction decay-FID) is by means of a mathematical procedure known as Fourier transform, which converts the FID into a frequency domain function (the spectrum) (8, 9) . Although a detailed discussion is out of the scope of this manuscript, processing of 1 H-MRS data based on the Fourier transform comprises several fundamental operations (7) (8) (9) (10) (11) (12) . First, zero filling of the FID is used to increase resolution by inserting additional data points of zero amplitude. Second, a window function is applied to either increase resolution or to improve SNR. When it is used to remove truncation artifacts, this operation is known as apodization. Third, phase correction is applied in order to have all the resonances of the spectrum in the same phase (i.e., all peaks are pointing upwards). Finally, other typically applied processing operations are baseline correction (spectra are distorted secondary to the presence of intense residual water and/or lipid peaks), eddy current, and field inhomogeneity corrections, and postacquisition removal of water.
MRS data evaluation
The obtained spectrum represents specific metabolites appearing in certain frequencies due to their specific chemical shifts. The resonance spectrum identifies metabolites by locating their peaks. Several peaks can characterize the same compound (i.e., doublet or triplet). Graphic representation of acquired data includes these metabolite peaks (represented on the horizontal axis of the graph) expressed as parts per million (ppm) and their relative signal amplitude in the vertical axis. The area or integral under each peak represents the relative concentration of the detected metabolite (7) (8) (9) (10) (11) (12) . Magnetic resonance spectra are evaluated in clinical practice in three ways: qualitative evaluation, semiquantitative evaluation, and absolute quantification. Qualitative evaluation is performed by observing absence, presence, or change of a specific metabolite. Semiquantitative evaluation is performed by the calculation of amplitude or integral of the metabolite peaks. When using frequency domain methods, the area under the peaks of interest can be obtained using either the traditional running integral or by deconvolution (Fig. 3b) . Metabolite ratios, which are much more reproducible, are commonly used for evaluation (e.g., in prostate, choline+creatine/citrate ratio correlates significantly with the probability of malignancy) (Fig. 4) . Absolute quantification of the concentration of a metabolite can be obtained using a reference standard for calibration.
Clinical value of MRS in oncology
Although MRS was initially developed for the assessment of brain tumors, metabolic information obtained by MRS can be helpful in diagnosis and monitoring of different tumors. Actually, this is an established imaging technique in brain, prostate, and breast cancers (1) (2) (3) (4) . MRS interpretation is mainly based on checking the elevation of certain metabolites (such as choline) or the absence or decrease of normal metabolites (e.g., N-acetylaspartate-NAA-in the brain). A multiparametric imaging assessment of tumors, which may include MRS, represents an attractive approach for mapping the heterogeneity of tumor phenotype. This complex evaluation supposes an important challenge in order to integrate the great volume of information that imaging can offer. Apart from these tumors, there is a growing use of MRS in the evaluation of different tumor types, but its value depends on the clinical scenario (e.g., organ, tumor type).
Brain tumors
Diagnosis of intracranial masses based on imaging findings alone is a challenge for imaging. H-MRS spectra. Reduced enhancement and decreased tumor size is seen after treatment. However, an increased choline/Nacetylaspartate (NAA) ratio suggests no tumor response. These apparent contradictory findings may be secondary to the restoration of the blood-brain barrier as a result of antiangiogenic therapy. This feature explains a lower enhancement on T1-weighted contrast-enhanced image following therapy and a reduction in edema, which may be responsible for the changes in T2 image. Although these imaging findings may suggest tumor response, MRS findings do not support it, reinforcing the role of a multiparametric evaluation of the tumor phenotype.
level to define the spatial extent of the tumor or to distinguish tumor from other neurologic abnormalities, because NAA is reduced in other neuropathologic entities like multiple sclerosis and Alzheimer disease (15, 16) . The increased choline peak in brain tumors indicates an elevated rate of membrane turnover. Elevated choline along with decreased NAA is a diagnostic feature of brain tumors. The choline/NAA ratio increases as the grade increases. In addition, a peak of lipids associated with necrosis or hypoxia is found in high-grade tumors. Although an increased choline peak has been found to correlate well with cellular density, cell proliferation indices (such as Ki-67), and the degree of tumor infiltration (14, 15) , this is not a specific marker for neoplastic lesions of the central nervous system. Spectra from active plaques in multiple sclerosis show an elevated choline/creatine ratio and normal or reduced NAA/creatine ratio. Chronic multiple sclerosis plaques in white matter show a reduced NAA/creatine ratio and, sometimes, an elevated choline/ creatine ratio, but the ratio is not as high as in tumors. The creatine peak may vary with the tumor type and the grade of glioma. It is thought that the observed decrease in the creatine peak is related to an increased metabolic rate of the tumor, but the specific biochemical mechanisms leading to these changes are not well understood (15) . There is often a mild increase of creatine signals in low-grade astrocytomas, followed by progressive depletion with increasing anaplasia. In gliomatosis cerebri, creatine peak may be also elevated. On the contrary, creatine is virtually absent in lymphomas and metastases and low in meningiomas and oligodendrogliomas. Lipids are also important metabolites. The presence of lipid peaks at 1.3 and 0.9 ppm is a usual finding of glioblastoma, metastases, lymphoma, and abscesses. The biological basis of the increased lipids is presumed to be secondary to necrosis and membrane breakdown. Recent studies have shown that the lipid resonance observed in MRS may be produced during changes in cellular proliferation that occur prior to the onset of necrosis or products of apoptotic processes (17) . On the other hand, large amounts of lipids can also be found in areas treated with radiotherapy (18) . Another important metabolite peak, lactate, is secondary to anaerobic glycolysis, tumor ischemia, or necrosis. Lactate peak is found mainly in high-grade gliomas, but recent studies evidenced that their presence is not a reliable indicator of tumor grade, as they are found in all pediatric brain tumors regardless of histologic grade (14) (15) (16) 18) . Lactate may also be detected in the necrotic areas of glioblastoma and metastases. A myoinositol peak is typically present in glial tumors even in the absence of increased choline. It is generally higher in low-grade astrocytomas and gliomatosis cerebri (14) (15) (16) . The rapid T2 relaxation of myoinositol requires a short TE MRS sequence for detection. Glx resonances are also most easily detected with short TE sequences, but are difficult to quantify due to the characteristic-rolling baseline of short TE spectra. Despite this difficulty, several studies have reported elevated Glx in meningiomas relative to normal brain and astrocytomas. Finally, alanine is occasionally found in the spectrum of meningiomas and abscesses. Alanine resonates at 1.47 ppm and is a J-coupled, doublet peak that is inverted at TE values between 135 and 144 ms. It may also overlap with lactate to form an apparent "triplet peak". As shown, the combination of changes in different metabolites is useful in the differential diagnosis of brain lesions (Table 2) . However, lesion variability, heterogeneity, and overlap between different tumor types can make characterization difficult. Other important oncologic features can be evaluated using MRS imaging. Survival time appears to be negatively associated in patients with glioma grade IV containing large areas of abnormal metabolism (high lactate and lipid levels) (19) . Besides, tumors are commonly quite heterogeneous. The use of magnetic resonance perfusion imaging may help to localize the best area for spectral evaluation (20) . This feature may be useful in order to use MRS imaging for selecting representative areas of the tumor for biopsy. In this setting, low-grade areas of a glioma are generally characterized by relatively high NAA/choline ratios; while high-grade areas are usually marked by lactate and lipid peaks (13) . Ideally, regions of high metabolic activity should be sampled. Finally, elevation of choline has been recognized as an important surrogate marker of tumor progression and response to therapy (14, 15) . 1 H-MRS has also been applied to differentiate radiation-induced tissue injury from relapsing tumor. Increased choline signal is suggestive of tumor recurrence (21) .
Breast cancer
Breast MRI shows high sensitivity but limited specificity for cancer detection. Several studies have reported the role of total choline as a marker of breast cancer (Fig. 1)  (22-27) . Adding 1 H-MRS to breast MRI may improve the specificity of breast cancer detection from 70% up to 92% (23) (24) (25) . Dynamic contrast-enhanced acquisition may help identify enhancing areas in the tumor (usually associated to an increased metabolism) suitable for spectroscopic examination (26) . However, several technical constraints must be considered in breast MRS. In lesions less than 2 cm in diameter, MRS may show a reduced SNR of choline resonance. Although any value of TE can be used in breast 1 H-MRS, the scientific published literature recommends the use of long TEs (>135 ms). Despite these challenges, several studies have demonstrated that MRS may differentiate benign and malignant lesions in the breast (22) (23) (24) (25) (26) (27) (28) . Lesions with detectable choline peaks are suspicious for malignancy, with sensitivity and specificity rates reported as 83% and 85%, respectively (29) . Choline quantification in a lesion is considered positive when the peak of total choline at 3.2 ppm is two-times above the baseline (30) . Another potential use of in vivo spectroscopy is to monitor tumor response to chemotherapy with a diminution of total choline detected in responder breast cancers to neoadjuvant chemotherapy. However, there is still no consensus on the role of MRS for assessing the tumor response (31) .
Prostate cancer
MRS may be used for detection, localization, staging, tumor aggressiveness evaluation, and tumor response assessment of prostate cancer (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) ; however, its value in some of these indications has been subject to discussion (39, 41, 43) . The use of endorectal coil in prostate MRI may be particularly valuable for inherently lower SNR sequences, such as MRS (39) . The use of a higher magnetic field strength (3.0 T) along with endorectal coil results in higher SNR and improved spectral resolution. Main peaks observed in MRS spectra of the prostate are citrate, creatine, and choline compounds. However, different anatomic zones of the healthy prostate show different amplitudes for these metabolites as well as different (choline+creatine)/citrate integral ratios (33) . Citrate is produced in the epithelial cells as an intermediate product in the Krebs cycle. It accumulates in the luminal space of the prostate. The lower citrate peak in prostate cancer is secondary to altered metabolism and reduction of luminal space. Apart from its diagnostic value, MRS offers possibilities for a noninvasive assessment of prostate cancer aggressiveness in vivo. Compared with normal peripheral or benign prostate hyperplasia (BPH) tissues, citrate signals are reduced and those of choline compounds are often increased in prostate cancer (Fig. 4) . Combinations of different metabolite ratios have been evaluated for detecting aggressive tumors (32, 34, 35) . The maximum choline+creatine/ citrate ratio and the maximum choline/ creatine ratio correlated significantly with aggressiveness. However, owing to the presence of BPH, cancer in central gland is more difficult to discern (36) . A commonly used system for the evaluation of MRS in prostate was developed by Jung et al. (37) , which reported a standardized scoring system for the evaluation of the spectral data of the peripheral and central gland zones. This scoring system uses a visual classification system and a threshold metabolite approach corresponding to the (choline+cre-atine)/citrate integral ratio. The accuracy of the scoring system improved when at least three adjacent voxels showed abnormal findings (metabolite peaks are greater than five times the standard deviation of noise level). This classification showed good accuracy in differentiating benign from malignant lesions and excellent interobserver agreement. A multiparametric imaging assessment of prostate lesions based on the Prostate Imaging-Reporting and Data System (PI-RADS) also included a classification of MRS findings for lesion evaluation (Fig. 4) (38) . However, it must be remarked that the new version of this scoring system (PI-RADS v2) does not include the use of MRS, perhaps due to its technical complexity (39) . MRS may also be useful in image-guided focal therapy (40) and to evaluate prostate cancer response to different therapies (41) . In case of androgen deprivation therapy, metabolic evaluation might be challenged. The secondary glandular atrophy causes a reduction of citrate peaks in both tumor and in normal glandular areas and only a slow reduction of choline and creatine peaks in tumor. On the other hand, persistent elevation of choline levels can also indicate ongoing active disease in the prostate gland. Finally, in the evaluation of prostate MRS findings, sources of false positive/negative findings must be considered. False positive may be secondary to areas/ lesions that show either reduced citrate levels (i.e., the anterior fibromuscular stroma or stromal BPH nodules) or elevated choline levels, such as in the vicinity of seminal vesicles or in the periurethral zone (due to elevated levels of glycerophosphocholine in the seminal fluid) or in areas of prostatitis. On the other hand, false negative findings can occur with small or infiltrating lesions.
Head and neck cancer
Main clinical applications of MRS in the head and neck area include characterization of the head and neck masses, prediction of treatment response to therapy, and monitoring patients with head and neck cancer undergoing therapy (44) . In this setting, previous articles evidenced higher choline/creatine ratios in squamous cell carcinoma compared with normal tissues (i.e., muscle). On its part, lymphomas showed higher ratios than that of the carcinomas, which was attributed to high cell density of the lymphomas (44, 45) . Concerning tumor response evaluation, King et al. (46) reported that the presence of a choline peak in a post-treatment mass might be a marker of residual cancer. Future applications may include characterization of the lymph nodes. The metastatic lymph nodes showed a significantly higher choline/creatine ratio compared with benign lymphoid hyperplasia (5).
Hepatobiliary system
There is limited use of MRS in the hepatobiliary system (Table 3) . Main limitation of MRS in the hepatobiliary system and gastrointestinal tract is motion. The MRS acquisition and processing protocol can be improved by introducing a control of respiratory motion using breath-hold acMagnetic resonance spectroscopy in oncology • 81 Figure 6 . A 68-year-old man with hepatocellular carcinoma. Axial contrast-enhanced T1-weighted gradient-echo image in the delayed phase demonstrates a big encapsulated mass (arrows). Single-voxel MR spectrum depicts a choline peak within this mass.
quisitions and an abdominal compression belt. Pre-and postprocessing including automatic phase and frequency correction may remove potential distortions introduced mainly by motion. To our knowledge, up to date there is no added value in using MRS in these fields. Application of 1 H-MRS studies in the liver aim to characterize the hepatic mass or monitor hepatocellular carcinoma (HCC) treated with chemoembolization. In this setting using a short TE, various groups found that malignant liver tumors present higher levels of choline compared with uninvolved liver or benign tumors (47) (48) (49) (Fig. 6) . Kuo et al. (47) reported significant decrease of the total choline in the HCC after transcatheter arterial chemoembolization, while lipid and water signals were increased. On the contrary, Fischbach et al. (50) did not observe any significant difference between malignant liver tumors and normal liver parenchyma for the total choline. Due to these divergences, recent studies evaluated the possibility of quantification of choline in the liver. Xu et al. (51) concluded that lipids could mask the resonance signal of choline. However, the ability to reliably distinguish benign and malignant tumors from normal liver parenchyma has yet to be established.
In the pancreas, the main challenge for the radiologist is diagnosing pancreatic cancer. Unfortunately, choline, a classic marker of cancer, is also present in normal parenchyma (52) . Several authors indicate lipids as potential markers of pancreatic cancer (53, 54).
Gastrointestinal tumors
A few studies evaluated the value of 1 H-MRS in gastrointestinal tumors. Kim et al. (55) proposed using 1 H-MRS to diagnose rectal cancer and monitor treatment response after chemoradiotherapy. They found that after treatment, choline peak disappeared, resulting in only the lipid peak at 1.3 ppm in 97% of patients (Fig.  7) . Previously, Dzik-Jurazs et al. (56) had detected the same metabolites (choline and lipids) in rectal cancers. Mun et al. (57) used 1 H-MRS to determine the characteristics of gastric cancers and found that cancer lesions showed increased choline peaks, decreased lipid levels, and significant lactate doublet peaks in short TE compared with noncancerous gastric tissue. 
Genitourinary tumors (excluding prostate)
There is limited experience with the use of MRS in the evaluation of female pelvic lesions due to the wide range of pathological types of neoplasms with different behaviors (Table 4 ). In general, there was no statistically significant difference between choline levels in various types of gynecologic tumors or between benign and malignant lesions (Fig. 8) (58) . However, there are some contradictory data. In studies regarding the uterine tumors, Okada et al. (59) and Celik et al. (60) found that choline was present in benign and malignant lesions, while Takeuchi et al. (61) reported that malignant lesions have higher levels of choline, and a cutoff of 7 mmol might distinguish between them with 83% sensitivity and 93% specificity. Lipid peaks also showed promising results for distinguishing uterine sarcomas from benign leiomyomas (62) . In the case of tumors of the cervix, unfortunately choline is present in normal and tumor tissue without any detectable differences between them (58, (63) (64) (65) (66) (67) . Concerning ovarian tumors, different authors found higher levels of choline in malignant lesions, in tumors as well as metastatic lesions (68) . Stanwell et al. (69) determined that the choline/creatine ratio could distinguish between benign and malignant ovary lesions, thus a choline/creatine integral ratio >3 indicated a malignant tumor, whereas a choline/creatine integral ratio less than 1.5 indicated a benign nature. H-MRS pattern: first, an increase in the choline peak after puberty due to initiation of spermatogenesis and second, a decrease of the lipid peak secondary to increased testosterone synthesis in the testicular tissue, initiated by puberty. They found statistically significant differences between choline/lipid ratios of pre-and postpubertal males. In this setting, Aaronson et al. (73) studied three histologic patterns in 27 snap-frozen testicular tissues using 1 H-MRS: normal spermatogenesis, maturation arrest, and Sertoli-cell-isolated histology. They found that choline concentrations were higher in patients with normal spermatogenesis compared with those having Sertoli-cell-isolated histology. Preliminary results also reported that normal testis presents naturally high levels of choline; however, several causes of infertility (such as varicoceles or testicular tumors) decreases these levels due to a failure of spermatogenesis ( Fig. 9) (74) .
Soft-tissue tumors
1 H-MRS may help differentiate benign and malignant soft tissue lesions. Absence of choline peak is highly predictive of benign soft tissue lesions as shown by Russo et al. (75) using SVS and long TE. Previously, Subhawong et al. (76) revealed that a discrete choline peak had 88% sensitivity and 68% specificity in detection of malignant musculoskeletal lesions (Fig. 10) . Similarly, Doganay et al. (77) reported that choline had 72.2% sensitivity and 83.3% specificity in detecting malignant bone and soft tissue tumors.
MRS challenges
Nowadays most clinical MRI scanners have routine sequences for 1 H-MRS measurements, providing a wide range of metabolic information integrated with complementary anatomical or functional MRI sequences. However, MRS shows considerable technical complexity, is time consuming, offers lower sensitivities, and requires complex data processing (Table 5 ). MoreMagnetic resonance spectroscopy in oncology • 85 Baseline correction (MR spectra usually exhibit baseline distortions caused by the corruption of the first few data points in free induction decay or due to the superposition of broad lines arising from lipids or macromolecules. Water suppression also leads to baseline imperfections) J-modulation of multiplet resonances MRI instruments with a higher field strength (Some metabolite signals exhibit complex multiplet structures due to the effect of Improve localization performance and try to shorten the TE J-coupling) (The short TE stimulated echo acquisition mode or STEAM is less sensitive to J-coupling)
Homodecoupled or pure-shift experiments (where the indirect scalar couplings are removed)
Gibbs ringing at tissue boundaries Apply k-space filters in image reconstruction that suppress the outer regions of k-space (At the cost of reduced spatial resolution)
Metabile peak separation MRI systems with a higher field strength Two-dimensional MRS at higher magnetic field strengths to separate the overlapping peaks in an orthogonal dimension Homodecoupled or pure-shift experiments (where the indirect scalar couplings are removed) Quantification (MRI scanners are generally not designed to measure absolute signal levels) Metabolite ratios show good correlation with malignancy and can be used to identify suspicious areas Absolute concentration measurements can be obtained by calibration of measured metabolite signals against a reference signal produced by a material having a known concentration (e.g., an external phantom or an internal tissue)
Improve quantification by correcting T1-related signal saturation and T2 relaxation of the metabolite signals and the reference water signal Improved data processing and quantitation algorithms MRS, magnetic resonance spectroscopy; MRI, magnetic resonance imaging; STEAM, stimulated echo acquisition mode; PRESS, point-resolved spectroscopy; TE, echo time.
over, this technique needs radiologists' expertise and clinicians are unfamiliar with it. Finally, in many cases, it is not clear how the inclusion of MRS imaging might affect clinical decision-making and outcomes. All these factors continue to limit the application of MRS in the clinical setting (2, 4, 9, 10).
Conclusion
In conclusion, 1 H-MRS technique can aid in the management of cancer patients, serving as a noninvasive biomarker of metabolism in tumors. 1 H-MRS has achieved great strides as a molecular imaging technique since its introduction, and its scope in many clinical scenarios and research settings is rising. However, MRS needs expertise and is time consuming, which limit its clinical applicability. In this setting, spectra analysis needs to be simplified. Future work should also be concentrated on the evaluation of changes in the spectral pattern as an indicator of response during treatment of malignant disease. 
